Pellepharm, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.pellepharm.com
Clinical Trials
18
Active:14
Completed:4
Trial Phases
3 Phases
Phase 1:14
Phase 2:2
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Phase 1
14 (77.8%)Phase 2
2 (11.1%)Phase 3
2 (11.1%)Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- PellePharm, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02828111
- Locations
- 🇺🇸
12121 Bluff Creek Drive Suite 100, Los Angeles, California, United States
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- PellePharm, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT02762084
- Locations
- 🇬🇧
Royal London Hospital, London, United Kingdom
🇬🇧Manchester Royal Infirmary, Manchester, United Kingdom
News
No news found